Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
Clinical trial NCT05807776 · COMPLETED
Trial details
- NCT number
- NCT05807776
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-24
- Primary completion
- 2024-07-24
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.